We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.82%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$13.3B
AUM Growth
+$1.51B
Cap. Flow
+$1.01B
Cap. Flow %
7.58%
Top 10 Hldgs %
83.56%
Holding
124
New
10
Increased
16
Reduced
22
Closed
5

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$1.09B
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$84.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$44.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$144M
2
ABLX
Ablynx NV
ABLX
+$119M
3
NKTR icon
Nektar Therapeutics
NKTR
+$29.3M
4
EXEL icon
Exelixis
EXEL
+$13.4M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.38%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
51
Exelixis
EXEL
$14B
$11M 0.08%
513,410
-649,234
-56% -$13.4M
ALBO
52
DELISTED
Albireo Pharma Inc
ALBO
$8.88M 0.07%
250,000
– –
IFRX icon
53
InflaRx
IFRX
$245M
$8.35M 0.06%
258,824
+58,824
+29% +$2.03M
XLRN
54
DELISTED
Acceleron Pharma
XLRN
$7.95M 0.06%
163,900
– –
PGNX
55
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$7.87M 0.06%
979,016
-1,327,168
-58% -$10.1M
GLMD icon
56
Galmed Pharmaceuticals
GLMD
$4.31M
$7.57M 0.06%
+3,534
New +$5.12M
FOMX
57
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$7.47M 0.06%
1,490,201
-108,790
-7% -$560K
GTHX
58
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$7.37M 0.06%
169,492
– –
MNTA
59
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$6.31M 0.05%
308,500
– –
AUTL
60
Autolus Therapeutics
AUTL
$378M
$6.3M 0.05%
+235,294
New +$6.22M
VNDA icon
61
Vanda Pharmaceuticals
VNDA
$301M
$5.91M 0.04%
310,354
-290,000
-48% -$4.85M
SYRS
62
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.87M 0.04%
57,484
– –
ASMB icon
63
Assembly Biosciences
ASMB
$494M
$5.83M 0.04%
12,382
-3,767
-23% -$1.99M
VYNE icon
64
VYNE Therapeutics
VYNE
$5.68M 0.04%
194
– –
ACHN
65
DELISTED
Achillion Pharmaceuticals
ACHN
$5.5M 0.04%
1,943,620
-913,017
-32% -$3.11M
CCXI
66
DELISTED
ChemoCentryx, Inc.
CCXI
$5.45M 0.04%
414,029
– –
ANAB icon
67
AnaptysBio
ANAB
$1.53B
$5.19M 0.04%
73,086
-18,000
-20% -$1.51M
CARM
68
DELISTED
Carisma Therapeutics
CARM
$5.12M 0.04%
+131,221
New +$5.78M
ACOR
69
DELISTED
Acorda Therapeutics
ACOR
$4.97M 0.04%
+1,443
New +$4.42M
ARAV
70
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.91M 0.04%
404,385
+166,667
+70% +$1.72M
CBIO
71
Crescent Biopharma
CBIO
$566M
$4.7M 0.04%
2,912
-2,721
-48% -$4.68M
LJPC
72
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.51M 0.03%
154,675
– –
GNMX
73
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.5M 0.03%
4,055,142
– –
MGNX icon
74
MacroGenics
MGNX
$235M
$4.5M 0.03%
217,695
-145,981
-40% -$3.29M
ADMS
75
DELISTED
Adamas Pharmaceuticals
ADMS
$4.46M 0.03%
172,630
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Baker Bros. Advisors held 124 positions worth $13.3B, up 13% from $11.8B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors deployed $1.01B of net new capital in Q2 2018, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Exelixis, an estimated $13.4M trimmed.

  • Baker Bros. Advisors's largest Q2 2018 buy was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q2 2018, an estimated $1.09B increase.
  • Baker Bros. Advisors's biggest Q2 2018 reduction was Exelixis, cutting an estimated $13.4M.
  • Baker Bros. Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $13.3B portfolio in Q2 2018.
  • Baker Bros. Advisors opened 10 new positions and closed 5 in Q2 2018.
  • Baker Bros. Advisors's portfolio value rose 13% quarter-over-quarter to $13.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.